1394 related articles for article (PubMed ID: 18275896)
1. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
3. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
[TBL] [Abstract][Full Text] [Related]
5. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.
Tanimoto TE; Yamaguchi T; Tanaka Y; Saito A; Tajima K; Karasuno T; Kasai M; Kishi K; Mori T; Maseki N; Morishima S; Miyakoshi S; Kasai M; Ohno Y; Kim SW; Numata A; Kami M; Takaue Y; Mori S; Harada M
Br J Haematol; 2004 May; 125(4):480-93. PubMed ID: 15142119
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood stem cell transplantation in children with beta-thalassemia major.
Farzana T; Shamshi TS; Irfan M; Ansari SH; Baig MI; Shakoor N
J Coll Physicians Surg Pak; 2003 Apr; 13(4):204-6. PubMed ID: 12718774
[TBL] [Abstract][Full Text] [Related]
8. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
9. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
10. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
11. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow vs. peripheral blood stem cell transplantation: a long-term retrospective single-center analysis in 329 patients.
Auberger J; Clausen J; Kircher B; Kropshofer G; Lindner B; Nachbaur D
Eur J Haematol; 2011 Dec; 87(6):531-8. PubMed ID: 21848700
[TBL] [Abstract][Full Text] [Related]
13. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
[TBL] [Abstract][Full Text] [Related]
14. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group.
La Nasa G; Argiolu F; Giardini C; Pession A; Fagioli F; Caocci G; Vacca A; De Stefano P; Piras E; Ledda A; Piroddi A; Littera R; Nesci S; Locatelli F
Ann N Y Acad Sci; 2005; 1054():186-95. PubMed ID: 16339665
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
16. Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients.
Iravani M; Tavakoli E; Babaie MH; Ashouri A; Khatami F; Ghavamzadeh A
Exp Clin Transplant; 2010 Mar; 8(1):66-73. PubMed ID: 20199374
[TBL] [Abstract][Full Text] [Related]
17. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic peripheral blood stem cell transplantation for high-risk leukemia].
Huang X; Wang F; Guo N
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1348-51. PubMed ID: 11930625
[TBL] [Abstract][Full Text] [Related]
19. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
20. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
